Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689006 | 0.77 | CMA1 (0.44) | FFAR1FFAR4NR3C1 | |
| SCHEMBL3689705 | 0.76 | FFAR1 (0.39) | FFAR1S1PR1S1PR3FFAR4RAB9A | |
| SCHEMBL3689701 | 0.72 | LMNA (0.45) | FFAR1FFAR4NR3C1 | |
| SCHEMBL3686574 | 0.71 | FFAR1 (0.56) | FFAR1S1PR1S1PR3FFAR4POLB | |
| SCHEMBL5509232 | 0.70 | CHRM2 (0.50) | RAB9A | |
| SCHEMBL1980894 | 0.68 | CES2 (0.41) | TBXA2R | |
| SCHEMBL2941883 | 0.68 | LMNA (0.52) | TBXA2RALDH1A1 | |
| SCHEMBL193318 | 0.68 | FFAR1 (0.79) | FFAR1FFAR4 | |
| SCHEMBL15891020 | 0.66 | S1PR1 (0.81) | FFAR1S1PR1S1PR3S1PR5 | |
| Hydrochloric Acid SCHEMBL28568409 | 0.66 | FFAR1 (0.76) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | FFAR1 14/4885S1PR1 997/4885S1PR3 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.